with great interest. We wish to discuss the role of fibrates in the management of dyslipidaemia in patients with chronic kidney disease (CKD).
Statins substantially decrease cardiovascular disease (CVD) and mortality in patients with CKD who do not require dialy sis. [2] [3] [4] However, because serum levels of triglyceride-rich lipoproteins are increased in patients with CKD, particularly in those with diabetic nephropathy, non-HDL cholesterol could be a better biomarker of dyslipidaemia than LDL c holesterol in this population. 5 The amount by which triglyceride is lowered is approximately doubled if fibrates are used in addition to statins. Thus, fibrates are a second-line preventive therapy for patients in the general population with hypertriglyceridaemia and a residual elevation in the level of non-HDL cholesterol. However, their role in patients with CKD has yet to be defined. 6 Investigators in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study 7 randomly allocated 9,795 participants with type 2 diabetes mellitus to either fenofibrate (200 mg daily) or placebo, with a median follow-up period of 5 years. In this study, fenofibrate treatment reduced total cardiovascular events (HR 0.89, 95% CI 0.80-0.99). 7 This benefit did not differ significantly between groups with different estimated glomerular filtration rates. The investigators concluded that fenofibrate should be considered as an additional therapeutic option, along with conventional risk-factor management, to further reduce CVD events and m ortality and provide renoprotection to patients with diabetes, as well as to those with moderate renal impairment. 8 By contrast, in the Action to Control Cardiovascular Risk in Diabetes Lipid-lowering agents in chronic kidney disease: do fibrates have a role?
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(ACCORD) lipid trial, 9 the addition of fenofibrate (160 mg daily) to simvastatin treatment (10-40 mg daily) was assessed in 5,518 participants with diabetes. No significant difference was found in the primary outcome of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. In a meta-analysis, fibrates reduced the risk of albuminuria progression in patients with diabetes, and reduced the risk of major cardiovascular events and cardiovascular death (but not all-cause mortality) in patients with an estimated glomerular filtration rate of 30-59.9 ml/min/1.73 m 2 .
10
Fibrates also increase the serum creatinine level after therapy initiation, but this effect could be a response to the blunting of creatinine secretion rather than true renal injury. 11 In post-trial analysis of the FIELD 12 and ACCORD 9 data sets, acute changes in the creatinine level with fibrate therapy were not associated with adverse effects on major clinical renal outcomes, and indeed suggest the possibility of long-term renal benefit. 10 Taken together, fibrates are likely to improve lipid profiles and prevent CVD in patients with CKD. However, the available data come from subgroup analyses of trials in broad populations, and no data are currently available for individuals with end-stage renal disease. Therefore, large-scale, prospective, randomized trials to assess the role of fibrates in reducing cardiovascular risk in patients with CKD, especially those with diabetic nephropathy, are urgently needed. 
